The Tree Frog's Gut May Be Hiding a New Weapon Against Cancer

 The next important cancer treatment might not come from an enormous pharmaceutical laboratory, an artificial intelligence system searching through millions of synthetic molecules, or some enormously expensive piece of medical technology. It might come from inside a frog.

Scientists at the Japan Advanced Institute of Science and Technology have identified a naturally occurring bacterium from the intestines of the Japanese tree frog that produced an extraordinary result in mice with colorectal cancer. A single intravenous treatment with the bacterium, Ewingella americana, completely eliminated the tumours in the experimental model. The researchers reported a 100 per cent complete-response rate, although the crucial qualification is that these were mice, not human cancer patients.

That qualification cannot be emphasised too strongly. Medical history is littered with cancer treatments that produced spectacular results in laboratory animals and then failed when researchers tried them in humans. Nobody should read this research and conclude that a cure for human cancer has been discovered. Nevertheless, the result deserves attention because of the remarkable way the bacterium apparently works.

The researchers did not begin with the assumption that tree frogs possessed some magical cancer cure. They investigated the gut microbiota of Japanese tree frogs, Japanese fire belly newts and Japanese grass lizards, collecting 45 bacterial strains and testing them for anticancer activity. Nine showed promising effects, but Ewingella americana emerged as the standout performer.

Cancer creates an unusual biological environment. Solid tumours frequently contain regions with very low oxygen levels, while their blood vessels can be abnormal and leaky. Cancer cells also manipulate the immune system to protect themselves from attack. These adaptations are useful to the tumour, but they may simultaneously create vulnerabilities. The frog bacterium appears capable of exploiting them.

E. americana is a facultative anaerobe, meaning that it can grow in both oxygen-rich and oxygen-poor environments. After being injected into the mice, the bacteria accumulated overwhelmingly within the tumours rather than healthy organs. Within 24 hours, the bacterial population inside the tumours increased approximately 3,000-fold. The very environment that helps malignant tissue survive may therefore provide a biological refuge in which these bacteria can multiply.

Then came the second attack. The bacteria did not merely damage cancer cells directly. Their presence apparently alerted the immune system. T cells, B cells and neutrophils moved into the tumour, accompanied by increased inflammatory signalling. The treatment therefore appears to work through a fascinating combination: the bacteria attack the tumour while simultaneously recruiting the animal's own immune defences against it.

Cancer is notoriously difficult to treat partly because it is not simply a foreign invader sitting passively inside the body. Tumours manipulate their local environment and evade immune surveillance. Modern immunotherapies attempt to remove some of those brakes and allow the immune system to recognise cancer again. Here, nature may have produced another possible route into the same battle.

The preliminary safety findings in the animals were also encouraging. The bacteria were rapidly removed from the bloodstream, becoming undetectable within 24 hours. Researchers reported no colonisation of major healthy organs including the liver, spleen, lungs, kidneys and heart. There was temporary mild inflammation, but it returned to normal within 72 hours, and researchers reported no evidence of chronic toxicity during the 60-day observation period.

Again, none of this establishes safety in humans. Injecting living bacteria into a person's bloodstream is obviously not something to be approached casually. Human immune systems may respond differently, and a bacterium that is manageable in a laboratory mouse could produce complications in a sick or immunocompromised cancer patient. Before anything resembling routine treatment could occur, there would have to be extensive additional research and ultimately carefully controlled human trials.

But the broader lesson is worth considering. For all our extraordinary technological sophistication, humanity has explored only a fraction of the biological chemistry surrounding us. Rainforests, oceans, soils, fungi, insects, reptiles and amphibians contain immense libraries of molecules and microorganisms produced by hundreds of millions of years of evolutionary competition.

Medicine has repeatedly raided that library. Penicillin famously emerged from mould. Numerous antibiotics came from microorganisms. Important cancer drugs have originated in plants and other natural sources. Nature does not manufacture these substances because it wants to cure human disease; organisms produce chemicals and biological strategies to survive their own struggles against predators, competitors and pathogens. Humans sometimes discover that these ancient biological weapons can be redirected for our purposes. The tree-frog research extends that principle into the microbiome.

The interesting point is not merely that bacteria live inside animals. We have known that for a long time. It is that an obscure microorganism occupying an obscure ecological niche might possess characteristics that make it extraordinarily well suited to attacking something as medically important as a solid tumour.

The researchers are now interested in whether the approach could extend beyond colorectal cancer to other solid tumours, including breast cancer, pancreatic cancer and melanoma. They also want to investigate different dosing methods, direct injection into tumours and combinations with chemotherapy or immunotherapy.

Whether any of that eventually works in humans remains unknown. Perhaps Ewingella americana will become an important part of future cancer medicine. Perhaps scientists will modify it, extract useful mechanisms from it or combine bacterial therapy with existing treatments. Perhaps human trials will expose difficulties that cannot be overcome and the discovery will become another interesting laboratory result that never reaches the clinic.

That uncertainty is how genuine science works. But there is something wonderfully humbling about the discovery nevertheless. We spend billions designing increasingly sophisticated technologies to defeat cancer, while an organism sitting unnoticed inside the intestine of a little Japanese tree frog may have evolved biological machinery capable of finding tumours, multiplying inside them, damaging cancer cells and calling in the immune system to finish the job.

https://www.tandfonline.com/doi/full/10.1080/19490976.2025.2599562

https://www.sciencedaily.com/releases/2026/07/260709160655.htm